MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the company's criteria. “It is a disappointment to discontinue the development program but our product candidates need to meet strict criteria to be approved for continued investments. Our other development programs progresses according to plan and our goal of positive cash flow and operating results 2013 remain unchanged,” said Peter Wolpert, CEO of Moberg Derma. About this information Moberg Derma discloses the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 16:00 pm (CET) on October 27th, 2011. For further information, please contact: Peter Wolpert, President and CEO of Moberg Derma Telephone: +46 8 522 307 00 Mobile: +46 70- 735 71 35 E-mail: peter.wolpert@mobergderma.se (peter.wolpert@mobergderma.se) Magnus Persson, IR Mobile: +46 73-355 26 01 E-mail: magnus.persson@mobergderma.se (magnus.persson@mobergderma.se)
MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ
| Source: Moberg Pharma AB